Japan Patent Allowed for Mastitis Treatment/ Prevention
illi News/10307441

CHICAGO - illiNews -- Braasch Biotech LLC, an emerging biopharmaceutical company pioneering a new field of anti-somatostatin vaccines, today announced a Notice of Allowance was received from the Japan Patent Office on July 15, 2025,  for Braasch's patent entitled "COMPOSITIONS FOR TREATMENT AND/OR PREVENTION OF MASTITIS."

The Patent Allowance provides claims for the therapeutic and preventative treatments for mastitis in milk production animals. Wherein the milk production animal exhibits significantly increased milk production within days of first vaccination, and does not exhibit loss of muscle mass, increased bone growth, injection site reaction, or hoof problems and decreased use of antibiotics.

The Braasch vaccine technologies, like other veterinary vaccines, utilize specific immunological responses post-vaccination. In the case of the Braasch vaccine, the endogenous hormone somatostatin is targeted. By attenuating the effects of this counter-regulatory hormone, a positive outcome is produced. Unlike other vaccines, the Braasch vaccine's mode of action is by B-cell epitope enhancements which produces an antibody response within 4 days (US Patent 10,441,652 B1, October 2019).

More on illi News

• Naper Pride Fest Returns for Its Fourth Year — A Celebration of Community, Inclusivity, and Pride
• Visitors to the Florida Keys Can Receive 15 Percent Off With The 90-Day Advance Purchase Rate Discount From KeysCaribbean
• Connect With Purple Wave Auction At Farm Progress Show
• The Emotional Side of Foreclosure: How 4Closure Rescue LLC Helps Families Find Hope in Crisis
• Unlocking Amazon Savings: How Seller Promotional Codes Work — And How to Find Them Legitimately

"We are pleased that the Japan Patent Office has recognized the vaccine's novelty and commercial utility in the areas of mastitis treatment and milk production enhancement," stated Jeralyn Braasch Haffer, CEO.

Braasch's intellectual property portfolio includes multiple patent families with issued or pending claims directed to utility of anti-somatostatin vaccine technologies, SomatovacÔ for multiple metabolic challenges. These applications relate to both human and veterinary use of the technologies.

About Braasch Biotech

Braasch Biotech is a biopharmaceutical company with a focus on the development and commercialization of innovative products of therapeutic approaches utilizing SomatovacÔ technologies. Currently in the Product Pipeline are vaccines for livestock productivity enhancement, increased fertility, GH/IGF-1 deficiencies and obesity treatment. To date, Braasch has multiple regulatory submissions in progress on the use of vaccines in metabolic regulation of dairy cows, pigs and obese pets. Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota.

For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.